- Home
- BCAT vs AGIO Comparison
BCAT vs AGIO Comparison
Compare BCAT & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BCAT | AGIO |
|---|---|---|
| Founded | 2020 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | BCAT | AGIO |
|---|---|---|
| Price | $14.21 | $24.62 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $32.13 |
| AVG Volume (30 Days) | 308.8K | ★ 1.6M |
| Earning Date | 01-01-0001 | 10-30-2025 |
| Dividend Yield | ★ 9.38% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.43 | N/A |
| Revenue | N/A | ★ $44,791,000.00 |
| Revenue This Year | N/A | $28.75 |
| Revenue Next Year | N/A | $139.45 |
| P/E Ratio | $11.41 | ★ N/A |
| Revenue Growth | N/A | ★ 36.26 |
| 52 Week Low | $13.67 | $22.24 |
| 52 Week High | $16.38 | $46.00 |
Technical Indicators
Market Signals| Indicator | BCAT | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 40.65 | 31.88 |
| Support Level | $14.19 | $24.16 |
| Resistance Level | $14.45 | $27.95 |
| Average True Range (ATR) | 0.12 | 1.03 |
| MACD | -0.02 | 0.21 |
| Stochastic Oscillator | 0.00 | 12.60 |
Price Performance
Historical ComparisonAbout BCAT BlackRock Capital Allocation Term Trust of Beneficial Interest
BlackRock Capital Allocation Trust is a non-diversified, closed-end management investment company. The investment objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.